SAB Biotherapeutics Inc. has announced a Special Meeting of Stockholders to be held in 2025 in a virtual format. During this meeting, stockholders will vote on key proposals, including the approval of the potential issuance of common stock in excess of 19.99% of the company's outstanding shares upon conversion of Series B Preferred Stock, and an amendment to the 2021 Omnibus Equity Incentive Plan.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001833214-25-000003), on August 19, 2025, and is solely responsible for the information contained therein.